Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

New CDER No. 2 May Impact FDA's Safety Monitoring Aspirations

Apr 18 2018

• By Derrick Gingery

FDAEntrance_1200x675

Related Content

US FDA Taps Pfizer Executive For CDER Deputy Director Slot

Feb 02 2018

FDA Highlights Advanced Drug Manufacturing Approaches In Budget Plan

Feb 13 2018

Orphan Drug Policy Changes To Be Considered Under US FDA's FY 2019 Budget Proposal

Apr 05 2018

Oncology Stakeholders Offer Niche Recommendations To US FDA, But Who Will Ultimately Get Their Way?

Mar 30 2018

US FDA May Create Immunology, Neuroscience Centers Of Excellence

Dec 02 2017

Don't Rush To Reorganize FDA, McClellan Says

Feb 29 2016

Moscicki's Move From FDA To PhRMA About 'Best' Use Of Leadership Skills

Oct 19 2017

FDA Searches Small Industry Candidate Pool To Fill Executive Vacancies

Mar 24 2014

Merck R&D Exec Jumps To US FDA As Office Of New Drugs Deputy Director

Nov 09 2016

Related Companies

Pfizer Inc.

Sanofi

Eli Lilly and Company

Sanofi Genzyme

Merck & Co., Inc.

Additional Topics

United States FDA Leadership Regulation Safety BioPharmaceutical

More from US FDA

More from Agency Leadership

About Us

Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us

Customer Service
SubscribeOpens in new window
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window